Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE

Full Text:

Abstract

pharmacoepidemiology is a well recognized throughout the world scientific discipline studying the use of and the effects of drugs in the whole population or in large groups of people in order to improve efficacy and safety of pharmacotherapy. Despite its relatively short history pharmacoepidemiology demonstrated significant influence on public health, due to new findings in efficacy and safety, broadening of indications lists for well recognized drugs, as well as changes in treatment strategies and prognosis for many socially-significant disorders. The history of pharmacoepidemiological studies, their methodology, practical application as well as special aspects and prospects of pharmacoepidemiology development in Russia are described in the article.

About the Authors

S. A. Rachina
Smolensk State Medical Academy
Russian Federation
MD, PhD (Smolensk, Russia)


R. S. Kozlov
Smolensk State Medical Academy
Russian Federation
MD, PhD, Prof. (Smolensk, Russia)


Yu. A. Belkova
Smolensk State Medical Academy
Russian Federation


References

1. Bel'kova Ju.A., Rachina S.A., Kozlov R.S., Mishhenko V.M., Kozhuhova L.L. , Abubakirova A.I. i soavt. Potreblenie i zatraty na sistemnye antimikrobnye preparaty v mnogoprofil'nyh stacionarah Rossijskoj Federacii i Respubliki Belarus': rezul'taty mnogocentrovogo farmakojepidemiologicheskogo issledovanija. Klin. mikrobiol. antimikrob. himioter. 2012; 14: 322-41.

2. Bodjaeva E.V. Rachina S.A., Otvagin I.V., Gudkov I.V. Analiz jeffektivnosti kompleksnogo vmeshatel'stva u pacientov s ostrym tonzillofaringitom v ambulatornoj praktike Smolenska. Klin. mikrobiol. antimikrob. himioter. 2011; 13: 46-55.

3. Golub A.V. Pokazateli kachestva i puti uluchshenija antibakterial'noj profilaktiki v abdominal'noj hirurgii. Avtoref diss. … kand. med. nauk. Smolensk. 2007; 23 s.

4. Kliniko-jekonomicheskie issledovanija. Dostupno na sajte: http://www.hta-rus.ru/research-2/.

5. Kozlov S.N. Farmakojepidemiologicheskie podhody k optimizacii lekarstvennoj terapii vnebol'nichnyh infekcij v ambulatornyh uslovijah. Avtoref. diss. …dokt. med. nauk. Smolensk. 2004. 37 s.

6. Kozlov S.N., Rachina S.A., Andreeva I.V. Farmakojepidemiologija antiinfekcionnyh himiopreparatov. V kn.: L.S. Strachunskogo, Ju.B. Belousova, S.N. Kozlova. Praktiicheskoe rukovodstvo po antiinfekcionnoj himioterapii. Smolensk. 2007; 47-55.

7. Kozlov S.N., Rachina S.A., Strachunskij L.S. Farmakojepidemiologija. V kn.: V.G. Kukesa, A.K. Starodubceva. Klinicheskaja farmakologija i farmakoterapija. M. 2003; 134-136.

8. Leonova M.V., Belousov D.Ju., Shtejnberg L.L., Galickij A.A., Belousov Ju.B., analiticheskaja gruppa issledovanija PIFAGOR. Pervye rezul'taty farmakojepidemiologicheskogo issledovanija arterial'noj gipertonii PIFAGOR III. Kachestvennaja klinicheskaja praktika 2010; 1: 54-60.

9. Prikladnaja farmakojepidemiologija. Uchebnik pod red. akademika RAMN V.I. Petrova. M. 2008; 384 s.

10. Rachina S.A. Optimizacija ispol'zovanija antimikrobnyh preparatov v mnogoprofil'nom stacionare: chem mozhet byt' polezen analiz real'noj klinicheskoj praktiki? Moskovskij medicinskij zhurnal. 2012; 3: 5-11.

11. Rachina S.A., Andreeva A.S., Bedenkov A.V. ATC/DDD metodologija: osnovnye principy i prakticheskoe ispol'zovanie v issledovanijah potreblenija lekarstvennyh sredstv. Klinicheskaja farmakoloigja i terapija 2002; 11: 44-8.

12. Fletcher R., Fletcher S., Vagner E. Klinicheskaja jepidemiologija. Osnovy dokazatel'noj mediciny. 3-e izd. Perevod s angl. pod red. S.E. Bashhinskogo, S.Ju. Varshavskogo. M. 1998; 382 c.

13. Fokin A.A., Rachina S.A., Kozlov S.N. Issledovanija ispol'zovanija lekarstvennyh sredstv: metodologija provedenija i perspektivy prakticheskogo primenenija v Rossii. Klinicheskaja farmakologija i terapija. 2009; 18 (1): 1-7.

14. Shal' E.P. Kliniko-jekonomicheskie i farmakojepidemiologicheskie aspekty antibakterial'noj terapii respiratornyh infekcij v ambulatornoj praktike. Avtoref. diss. kand. med. nauk. Smolensk. 2013; 27 s.

15. Bombardier C. Research challenges; overview of epidemiological study design. J. Reumatol. 1998; 15 (17): 5-8.

16. Drug utilization studies. Methods and uses. Edited by Dukes M.N.G. WHO Regional Publications, European Series, WHO Regional Office for Europe. Copenhagen. Denmark. 1993; 45.

17. Educational Programs in Pharmacoepidemiology. Available from: http://www.pharmacoepi.org/resources/programs.cfm.

18. Einarson T.R., Bergman U., Wiholm B.-E. Principles and practice of pharmacoepidemiology. In: Speight T.M., Holford N.H.G., editors. Avery’s Drug Treatment. 4th ed. New Zealand: Adis International Limited. 1997; 371-392.

19. Engel A., Siderius P. The consumption of drugs. Report on a study 1966-1967. Copenhagen. WHO Regional Office for Europe. 1968 (EURO 3101).

20. European Drug Utilization Research Group. Available from: http://www.eurodurg.com/.

21. Guidelines for Good Pharmacoepidemiology Practices. Available from: http://www.pharmacoepi.org/resources/guidelines_08027.cfm.

22. Guidelines for ATS classification and DDD assignment. Oslo, Norway: WHO Collaborating Centre for Drug Statistics Methodology. 2005.

23. Haaijer-Ruskamp F.M., Andersen M., Vander Stichele R.H. Prescribing Quality Indicators. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 197-218.

24. Hartzema A.G. Pharmacoepidemiology – its relevance to clinical practice. J. Clin. Pharm. and Therapeutics. 1992; 17: 73-74.

25. Hartzema A.G., Tilson H.H., Chan K.A. The Contribution of Pharmacoepidemiology to the Study of Drug Uses and Effects, and Risk Management. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 1-38.

26. Jones J.K., Tilson H.H., Lewis J.D. Pharmacoepidemiology: defining the field and its core content. Pharmacoepidemiol Drug. Saf. 2012; 21 (7): 677-689.

27. Kennedy D. Assessing national drug utilization in the United States. WHO Drug Utilization Research Group Meeting. 1983 Aug 5; Washington, USA.

28. Kurth T., Seeger J.D. Propensity Score Analyses in Pharmacoepidemiology. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008. p. 301-24.

29. Lee J.A.H., Draper P.A., Weatherall M. Prescribing in three English towns. Milbank Mem Fund Q 1965; 43: 285-290.

30. McBride W.G. Thalidomide and congenital abnormalities. Lancet. 1961; 2: 1358.

31. Meade T.W. Prescribing of chloramphenicol in general practice. BMJ. 1967; 1: 671-674.

32. Ronning M. Setting-up the WHO ATC classification of drugs and the Defined Daily Dose – problems and potential for standardizing drug use research worldwide. In: McGavock H., editor. Handbook of Drug Use Research Methodology. 1st ed. Newcastle: The United Kingdom Drug Utilization Research Group; 2000; 1-9.

33. Serradel J.S., Bjornson D.C., Hartzema A.G. Drug utilization study methodologies: national and international perspectives. Drug. Intell. Clin. Pharm. 1987; 21: 994-1001.

34. Stratchounski L.S., Andreeva I.V., Ratchina S.A., Galkin D.V., Petrotchenkova N.A., Demin A.A. et al. The inventory of antibiotics in Russian home medicine cabinets. Clin. Infect. Dis. 2003; 15; 37 (4): 498-505.

35. Strom B.L. Study Designs Available for Pharmacoepidemiology Studies. In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc. 2000; 17-30.

36. Strom B.L. What is pharmacoepidemiology? In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc.; 2000; 3-16.

37. Strom B.L. When Should One Perform Pharmacoepidemiology Studies? In: Strom B.L., editor. Pharmacoepidemiology. 3d ed. New York: John Wiley & Sons, Inc. 2000; 63-72.

38. Suruki R.Y., Chan K.A. Basic Pharmacoepidemiology Methods. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti. 2008; 219-38.

39. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). Guide on Methodological Standards in Pharmacoepidemiology (Revision 2). EMA/95098/2010. Available at http://www.encepp.eu/standards_and_guidances.

40. Urquhart J. Role of pharmacoepidemiology in drug development. Int. J. Clin. Pharm. Ther and Toxicol. 1992; 30: 456-458.

41. Verhamme K., Sturkenboom M. Study designs in paediatric pharmacoepidemiology. Eur. J. Clin. Pharmacol. 2011; 67 (1): 67-74.

42. Wettermark B. The intriguing future of pharmacoepidemiology. Eur. J. Clin. Pharmacol. 2013; 69 (1): 43-51.

43. Wettermark B., Vlahovic-Palcevski V., Salvesen Blix H., Rønn M., Vander Stichele R.H. Drug utilization research. In: Hartzema A.G., Tilson H.H, Chan K.A, editors. Pharmacoepidemiology and therapeutic risk assessment. Harwey Whitney Books, Cincinatti; 2008. p. 159-95.

44. WHO Drug Utilization Research Group (DURG). Validation of observed differences in the utilization of antihypertensive and antidiabetic drugs in Northern Ireland, Norway and Sweden. Eur. J. Clin. Pharmacol. 1985; 29: 1-8.

45. Wilson-Davis K. Study design and the use of statistics in drug use research. In: McGavock H., editor. Handbook of Drug Use Research Methodology. 1st ed. Newcastle: The United Kingdom Drug Utilization Research Group. 2000; 36-55.

46. World Health Organization Expert Committee. The selection of essential drugs. Geneva: World Health Organization, 1977.


For citation:


Rachina S.A., Kozlov R.S., Belkova Y.A. PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(1):33-39. (In Russ.)

Views: 1182


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)